Role of ADAMs 9 and 15 in Proliferative Retinopathy
Role of ADAMs 9 and 15 in Proliferative Retinopathy
批准号:
7280325
负责人:
Carl Peter Blobel
金额:
$51.38万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-06 至 2009-08-31
关键词:
Adam15 geneAdultAffectBlindnessCellsCleaved cellCytoplasmic TailDevelopmentDiseaseDisintegrin DomainDisintegrinsDrug DesignEndothelial CellsEpidermal Growth Factor ReceptorFertilizationGlycoproteinsGoalsHomeostasisKnock-in MouseKnockout MiceLIM DomainLigandsMalignant NeoplasmsMembraneMetalloproteasesModelingMolecularMusOutcomePathologic NeovascularizationPoint MutationProcessProteinsRegulationRetinaRetinal DiseasesRetinal NeovascularizationRetinopathy of PrematurityRoleSignal TransductionTNF geneTertiary Protein StructureTestingVascular Endothelial Growth Factor Receptor-2angiogenesiscadherin 5cardiogenesisextracellularmouse modelneovascularizationneurogenesisnotch protein
中文摘要
描述(由申请人提供):视网膜新生血管是失明的主要原因,因此我们需要提高对这种疾病的分子机制的理解,以提供更好的治疗选择。本研究的重点是了解两种膜锚定金属蛋白酶ADAMs(一种崩解素和金属蛋白酶)9和15在视网膜病理新生血管中的作用。我们已经证明,在早产儿视网膜病变模型(ROP模型)中,adam 15-/-小鼠强烈减少病理性新生血管形成,而adam 9-/-小鼠和adam 9/15-/-双敲除小鼠与野生型对照相比,强烈增加病理性新生血管形成。我们现在希望了解亚当斯9和15在增殖性视网膜病变中的作用机制。具体而言,我们将:
英文摘要
DESCRIPTION (provided by applicant): Retinal neovascularization is a major cause of blindness, and therefore improvements in our understanding of the molecular mechanism underlying this disease are needed to provide better options for treatment. This proposal focuses on understanding the role of two membrane-anchored metalloproteases, ADAMs (a disintegrin and metalloprotease) 9 and 15, in pathological neovascularization in the retina. We have shown that adam 15-/- mice have strongly decreased pathological neovascularization in a model for retinopathy of prematurity (ROP model), whereas adam 9-/- mice, and adam 9/15-/- double knockout mice have strongly increased pathological neovascularization compared to wildtype controls. We now wish to understand the mechanism underlying the role of ADAMs 9 and 15 in proliferative retinopathy. Specifically, we will:
i) Identify whether the metalloprotease domain or other domains of ADAMs 9 or 15 are critical for their role in pathological neovascularization using "knock-in" mice. The metalloprotease domain of ADAMs 9 and 15 may be involved in cleaving substrate proteins, the disintegrin domain/cysteine-rich region may function in cell-cell and cell matrix interactions, and the cytoplasmic domain may have a role in signaling. We will generate "knock-in" mice to evaluate the contribution of different domains to neovascularization.
ii) Search for potential substrates or interacting partners of ADAMs 9 and 15 that may be relevant for pathological neovascularization. The most likely hypothesis is that ADAM 9 and ADAM 15 cleave substrate oroteins with a role in angiogenesis. Protein ectodomain shedding is a well-established functional regulator of proteins such as TNFa, EGF-receptor ligands, and Notch and Delta. We will therefore test whether ADAMs 9 or 15, or other ADAMs cleave molecules with a role in angiogenesis, such as VEGFR-2, Tie-1 and 2, PECAM, VE-cadherin, etc. However, should "knock-in" mice demonstrate that regulation of angiogenesis is not due to the metalloprotease activity of ADAM 9 and 15, we will search for functionally relevant extracellular or cytoplasmic interacting proteins.
Since ADAMs 9 and 15 are not required for normal development and adult homeostasis, we anticipate that the proposed studies will provide new targets for the design of drugs that regulate pathological neovascularization without affecting normal angiogenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of iRhoms and ADAM17 in EGFR and TNFalpha signaling
-
批准号:10544994
-
项目类别:
-
资助金额:$41.14万
-
财政年份:2020
-
负责人:Carl Peter Blobel
-
依托单位:
Role of iRhoms and ADAM17 in EGFR and TNFalpha signaling
-
批准号:10316173
-
项目类别:
-
资助金额:$41.14万
-
财政年份:2020
-
负责人:Carl Peter Blobel
-
依托单位:
ADAMs: Key regulators of EGFR signaling
-
批准号:7922909
-
项目类别:
-
资助金额:$29.75万
-
财政年份:2009
-
负责人:Carl Peter Blobel
-
依托单位:
Matrix Metalloproteinases Gordon Conference
-
批准号:7425012
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2005
-
负责人:Carl Peter Blobel
-
依托单位:
Matrix Metalloproteinases Gordon Conference
-
批准号:7029006
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2005
-
负责人:Carl Peter Blobel
-
依托单位:
Role of ADAMs 9 and 15 in Proliferative Retinopathy
-
批准号:7768200
-
项目类别:
-
资助金额:$6.94万
-
财政年份:2004
-
负责人:Carl Peter Blobel
-
依托单位:
Role of ADAMs 9 and 15 in Proliferative Retinopathy
-
批准号:6807074
-
项目类别:
-
资助金额:$5.14万
-
财政年份:2004
-
负责人:Carl Peter Blobel
-
依托单位:
Role of ADAMs 9 and 15 in Proliferative Retinopathy
-
批准号:7123818
-
项目类别:
-
资助金额:$51.37万
-
财政年份:2004
-
负责人:Carl Peter Blobel
-
依托单位:
Role of ADAMs 9 and 15 in Proliferative Retinopathy
-
批准号:7483010
-
项目类别:
-
资助金额:$40.44万
-
财政年份:2004
-
负责人:Carl Peter Blobel
-
依托单位:
Role of ADAMs 9 and 15 in Proliferative Retinopathy
-
批准号:6946780
-
项目类别:
-
资助金额:$52.31万
-
财政年份:2004
-
负责人:Carl Peter Blobel
-
依托单位:
Role of ADAMs 9 and 15 in Proliferative Retinopathy
-
批准号:7081893
-
项目类别:
-
资助金额:$9.52万
-
财政年份:2004
-
负责人:Carl Peter Blobel
-
依托单位:
Role of ADAMs 9 and 15 in Proliferative Retinopathy
-
批准号:7080295
-
项目类别:
-
资助金额:$37.69万
-
财政年份:2004
-
负责人:Carl Peter Blobel
-
依托单位:
Functional and biochemical studies of ADAM19
-
批准号:6700807
-
项目类别:
-
资助金额:$25.57万
-
财政年份:2002
-
负责人:Carl Peter Blobel
-
依托单位:
ADAMs: Key Regulators of EGFR Signaling
-
批准号:8134725
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2002
-
负责人:Carl Peter Blobel
-
依托单位:
ADAMs: Key regulators of EGFR signaling
-
批准号:7348434
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2002
-
负责人:Carl Peter Blobel
-
依托单位:
ADAMs: Key regulators of EGFR signaling
-
批准号:7174765
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2002
-
负责人:Carl Peter Blobel
-
依托单位:
Functional and biochemical studies of ADAM19
-
批准号:6994066
-
项目类别:
-
资助金额:$2.33万
-
财政年份:2002
-
负责人:Carl Peter Blobel
-
依托单位:
ADAMs: Key Regulators of EGFR Signaling
-
批准号:9129170
-
项目类别:
-
资助金额:$11.73万
-
财政年份:2002
-
负责人:Carl Peter Blobel
-
依托单位:
ADAMs: Key Regulators of EGFR Signaling
-
批准号:8321956
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2002
-
负责人:Carl Peter Blobel
-
依托单位:
ADAMs: Key regulators of EGFR signaling
-
批准号:7578889
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2002
-
负责人:Carl Peter Blobel
-
依托单位:
海外基金